C A Hoefnagel, P A Voûte, J de Kraker, H R Marcuse
{"title":"Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.","authors":"C A Hoefnagel, P A Voûte, J de Kraker, H R Marcuse","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Total-body scintigraphy with 131I-meta-iodobenzylguanidine (131I-MIBG) was performed in 20 patients with neuroblastoma. In patients who were in complete remission no pathological concentration of 131I-MIBG was found. In 16 patients with residual, recurrent or metastatic neuroblastoma the tumor localizations were correctly identified by 131I-MIBG-scintigraphy In 5 patients additional tumor sites were found. In most patients an inverse relationship between myocardial and tumoral concentration of 131I-MIBG was noted. Dosimetric assessment of 131I-MIBG uptake in patients with metastatic disease revealed cases with considerable tracer concentration and long effective half lives in tumor localizations. It is concluded that 131I-MIBG total-body scintigraphy is useful in the diagnosis and follow-up of neuroblastoma and that therapeutic use of this agent is feasible, if patients are selected upon the merits of dosimetry.</p>","PeriodicalId":77706,"journal":{"name":"Diagnostic imaging in clinical medicine","volume":"54 1","pages":"21-7"},"PeriodicalIF":0.0000,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic imaging in clinical medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Total-body scintigraphy with 131I-meta-iodobenzylguanidine (131I-MIBG) was performed in 20 patients with neuroblastoma. In patients who were in complete remission no pathological concentration of 131I-MIBG was found. In 16 patients with residual, recurrent or metastatic neuroblastoma the tumor localizations were correctly identified by 131I-MIBG-scintigraphy In 5 patients additional tumor sites were found. In most patients an inverse relationship between myocardial and tumoral concentration of 131I-MIBG was noted. Dosimetric assessment of 131I-MIBG uptake in patients with metastatic disease revealed cases with considerable tracer concentration and long effective half lives in tumor localizations. It is concluded that 131I-MIBG total-body scintigraphy is useful in the diagnosis and follow-up of neuroblastoma and that therapeutic use of this agent is feasible, if patients are selected upon the merits of dosimetry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
